Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.99 0.04 (0.5%) Market Cap: 2.24 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 40/100

Iovance Biotherapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 16, 2022 / 04:40PM GMT
Release Date Price: $13.39 (+7.03%)
Mark Alan Breidenbach
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

All right. Hello, everyone. Thanks so much for joining us on Day 2 of Oppenheimer's 32nd Annual Healthcare Conference. My name is Mark Breidenbach, and my research team covers emerging biotechnology for OpCo.

The next presenting company is Iovance, which is developing a pipeline of tumor-infiltrating lymphocyte, or TIL, therapies for cancer, which we think are especially noteworthy because of their proven efficacy in solid tumors. Joining us for the discussion is the company's COO, Igor Bilinsky. We'll try and leave a few minutes at least at the end for Q&A. (Operator Instructions)

So with that said, let's dive right into the presentation. Igor, I'm going to hand over the mic to you.

Igor P. Bilinsky
Iovance Biotherapeutics, Inc. - COO

Thank you, Mark, and good afternoon, everyone. Great to be here today, and thanks for the opportunity to share Iovance's progress. We are a publicly listed company, and I'll be making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot